Los Angeles Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.42M | Buy |
89,637
+23,577
| +36% | +$792K | 0.01% | 466 |
|
|
2025
Q4 | $2.09M | Sell |
66,060
-3,013
| -4% | -$114K | 0.01% | 441 |
|
|
2025
Q3 | $1.96M | Sell |
69,073
-13,275
| -16% | -$397K | 0.01% | 512 |
|
|
2025
Q2 | $1.54M | Sell |
82,348
-22,107
| -21% | -$419K | 0.01% | 508 |
|
|
2025
Q1 | $1.88M | Buy |
104,455
+18,454
| +21% | +$374K | 0.01% | 411 |
|
|
2024
Q4 | $1.45M | Buy |
86,001
+11,499
| +15% | +$221K | 0.01% | 517 |
|
|
2024
Q3 | $1.21M | Buy |
74,502
+19,094
| +34% | +$224K | ﹤0.01% | 587 |
|
|
2024
Q2 | $455K | Sell |
55,408
-4,904
| -8% | -$51.3K | ﹤0.01% | 884 |
|
|
2024
Q1 | $893K | Buy |
60,312
+19,871
| +49% | +$268K | ﹤0.01% | 725 |
|
|
2023
Q4 | $586K | Hold |
40,441
| – | – | ﹤0.01% | 823 |
|
|
2023
Q3 | $437K | Buy |
40,441
+94
| +0.2% | +$1.13K | ﹤0.01% | 856 |
|
|
2023
Q2 | $520K | Buy |
40,347
+1,434
| +4% | +$19.4K | ﹤0.01% | 845 |
|
|
2023
Q1 | $514K | Sell |
38,913
-1,246
| -3% | -$19.8K | ﹤0.01% | 847 |
|
|
2022
Q4 | $602K | Buy |
40,159
+11,935
| +42% | +$109K | ﹤0.01% | 843 |
|
|
2022
Q3 | $333K | Buy |
28,224
+3,781
| +15% | +$51.1K | ﹤0.01% | 1042 |
|
|
2022
Q2 | $276K | Sell |
24,443
-710
| -3% | -$14.3K | ﹤0.01% | 1171 |
|
|
2022
Q1 | $752K | Hold |
25,153
| – | – | ﹤0.01% | 872 |
|
|
2021
Q4 | $667K | Hold |
25,153
| – | – | ﹤0.01% | 880 |
|
|
2021
Q3 | $913K | Sell |
25,153
-2,358
| -9% | -$92.8K | ﹤0.01% | 793 |
|
|
2021
Q2 | $1.19M | Sell |
27,511
-1,239
| -4% | -$46.8K | 0.01% | 780 |
|
|
2021
Q1 | $983K | Sell |
28,750
-53,992
| -65% | -$2.14M | ﹤0.01% | 901 |
|
|
2020
Q4 | $2.9M | Sell |
82,742
-11,397
| -12% | -$330K | 0.01% | 544 |
|
|
2020
Q3 | $2.26M | Buy |
94,139
+34
| +0% | +$835 | 0.01% | 538 |
|
|
2020
Q2 | $1.72M | Buy |
94,105
+39,537
| +72% | +$711K | 0.01% | 649 |
|
|
2020
Q1 | $851K | Buy |
54,568
+28,927
| +113% | +$616K | 0.01% | 755 |
|
|
2019
Q4 | $549K | Buy |
25,641
+8,051
| +46% | +$166K | ﹤0.01% | 992 |
|
|
2019
Q3 | $329K | Hold |
17,590
| – | – | ﹤0.01% | 1101 |
|
|
2019
Q2 | $459K | Hold |
17,590
| – | – | ﹤0.01% | 1069 |
|
|
2019
Q1 | $452K | Hold |
17,590
| – | – | ﹤0.01% | 1110 |
|
|
2018
Q4 | $405K | Sell |
17,590
-1,893
| -10% | -$53.4K | ﹤0.01% | 1019 |
|
|
2018
Q3 | $625K | Buy |
19,483
+7,090
| +57% | +$213K | ﹤0.01% | 1038 |
|
|
2018
Q2 | $351K | Buy |
+12,393
| New | +$441K | ﹤0.01% | 1243 |
|
|
2014
Q2 | – | Sell |
-16,131
| Closed | -$626K | – | 1274 |
|
|
2014
Q1 | $626K | Buy |
+16,131
| New | +$575K | 0.01% | 798 |
|
Other funds holding RIGL
AC
VCM
Los Angeles Capital Management's RIGL Position: Q1 2026 in Review
Los Angeles Capital Management increased its Rigel Pharmaceuticals (RIGL) stake by 36% in Q1 2026, buying an estimated $792K and bringing the position to 89,637 shares worth $2.42M. The position accounts for 0.01% of the portfolio, ranked #466.
Los Angeles Capital Management first reported a position in RIGL in Q1 2014 and has held it in 33 quarters since. The position peaked at $2.9M in Q4 2020. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Los Angeles Capital Management held 89,637 shares of Rigel Pharmaceuticals worth $2.42M as of Q1 2026.
- Los Angeles Capital Management bought 23,577 Rigel Pharmaceuticals shares in Q1 2026, an estimated $792K.
- Rigel Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #466 holding.
- Los Angeles Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2014 and has held it in 33 quarters since.
- Los Angeles Capital Management's Rigel Pharmaceuticals position peaked at $2.9M in Q4 2020.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.